Having trouble accessing articles? Reset your cache.

Inventiva discontinues lanifibranor for systemic sclerosis

Inventiva S.A. (Euronext:IVA) discontinued development of lanifibranor (IVA337) to treat diffuse cutaneous systemic sclerosis after the

Read the full 160 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE